Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2000 Mar 28;97(7):3370-5.
doi: 10.1073/pnas.97.7.3370.

Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice

Affiliations

Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice

S D Khare et al. Proc Natl Acad Sci U S A. .

Abstract

TALL-1/Blys/BAFF is a member of the tumor necrosis factor (TNF) ligand superfamily that is functionally involved in B cell proliferation. Here, we describe B cell hyperplasia and autoimmune lupus-like changes in transgenic mice expressing TALL-1 under the control of a beta-actin promoter. The TALL-1 transgenic mice showed severe enlargement of spleen, lymph nodes, and Peyer's patches because of an increased number of B220+ cells. The transgenic mice also had hypergammaglobulinemia contributed by elevations of serum IgM, IgG, IgA, and IgE. In addition, a phenotype similar to autoimmune lupus-like disease was also seen in TALL-1 transgenic mice, characterized by the presence of autoantibodies to nuclear antigens and immune complex deposits in the kidney. Prolonged survival and hyperactivity of transgenic B cells may contribute to the autoimmune lupus-like phenotype in these animals. Our studies further confirm TALL-1 as a stimulator of B cells that affect Ig production. Thus, TALL-1 may be a primary mediator in B cell-associated autoimmune diseases.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Histology analysis of TALL-1 transgenic mice. Sections of spleen (A–C), lymph node (D–F), and Peyer's patches (G–I) from control mice (Left) and TALL-1 transgenic mice (Right) were stained with hematoxylin and eosin (A, D, and G), anti-mouse B220 antibody (B, E, and H), or anti-mouse CD3 antibody (C, F, and I). Stained sections were analyzed under microscope at ×10.
Figure 2
Figure 2
FACS analysis splenocytes, lymph node cells, and thymocytes of TALL-1 transgenic mice. Single-cell suspensions were prepared from spleen, lymph nodes, and thymus from 10 TALL-1 transgenic mice and 5 control littermates. Cells were stained with FITC- or PE-conjugated monoclonal antibodies against Thy-1.2, B220, CD11b, Gr-1, CD4, or CD8.
Figure 3
Figure 3
Kidney Ig deposits in TALL-1 transgenic mice. Kidney sections of 5-mo-old control littermate (A–C), 5-mo-old TALL-1 mice (D–F), and 8-mo-old TALL-1 mice (G–I) were stained with hematoxylin and exosin (A, D, and G), anti-mouse IgM (B, E, and H), anti-mouse IgG (C, F, and I), and Trichrome (G, Inset). Stained sections were analyzed under microscope at ×60.
Figure 4
Figure 4
TALL-1 stimulates B cell survival and proliferation. (A) Increased B cell viability in TALL-1 transgenic mice. B cells were isolated from spleens of 3-mo-old TALL-1 transgenic mice (n = 3) and control littermates (n = 3). A total of 2.5 × 105 B cells was aliquoted per well in a 96-well round-bottom plate and incubated for 9 days. At the indicated days, cells were incubated with 5 μg/ml propidium iodide and subjected to FACS analysis for positive staining cells. Values are expressed as mean ± SEM. (B) TALL-1 stimulates B cell proliferation. Purified B cells (105) from B6 mice were cultured in triplicates in 96-well plate with indicated amount of TALL-1 at the absence (Upper) or presence of 2 μg/ml anti-IgM antibody (Lower) for a period of 4 days. Proliferation was measured by radioactive [3H]thymidine uptake in the last 18 h of pulse. Data shown represent mean ± SD of triplicate wells.

References

    1. Smith C A, Farrah T, Goodwin R G. Cell. 1994;76:959–962. - PubMed
    1. Lacey D L, Timms E, Tan H-L, Kelley M J, Dunstan C R, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, et al. Cell. 1998;93:165–176. - PubMed
    1. Chichepotiche Y, Bourdon P R, Xu J, Hsu Y M, Scott H, Hession C, Garcia I, Browning J L. J Biol Chem. 1997;272:32401–32410. - PubMed
    1. Mauri D N, Ebner R, Montgomery R I, Kochel R I, Cheung T C, Yu G L, Ruben S, Murphy M, Eisenberg R J, Cohen G H, et al. Immunity. 1998;8:21–30. - PubMed
    1. Hahne M, Kataoka T, Schroter M, Hofmann K, Irmler M, Bodmer I, Schneider P, Bornard T, Holler N, French L E, et al. J Exp Med. 1998;188:1185–1190. - PMC - PubMed